Skip to content

My Self-Sampling for HPV Awareness, Results, and Empowerment

A Technology-enhanced and Multilevel Approach to Promote Cervical Cancer Prevention Among Women Living With HIV

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07296159
Acronym
MySHARE+
Enrollment
130
Registered
2025-12-22
Start date
2027-01-01
Completion date
2029-08-31
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervical Cancer Screening, HPV

Keywords

Cervical cancer, HPV, HPV self-sampling, mHealth

Brief summary

The overall objective of this study is to conduct formative research and pilot test the provider-level and patient-level components of the My Self-Sampling for HPV Awareness, Results, and Empowerment (MySHARE+) intervention. MySHARE+ aims to harness the power of technology and apply a multilevel approach to promote the adoption of cervical cancer screening (HPV self-sampling; Pap triage adherence) among under/never-screened women living with HIV (WLH). The specific aims are to 1) identify facilitators and barriers to implementing a healthcare provider prompt in a primary care setting and 2) conduct a pilot randomized controlled trial (RCT) to examine the feasibility, acceptability, and preliminary efficacy of a mHealth educational intervention in promoting cervical cancer awareness and HPV self-sampling among WLH. Under aim 1: Providers of healthcare and/or social services to WLH will complete an online survey to identify barriers to implementing a healthcare provider prompt in a primary care setting and participate in semi-structured interviews to provide feedback on drafted prompts. Prompts will be piloted at one local clinic to improve patient-provider communication about cervical cancer screening, followed with semi-structured interviews with providers involved. Under aim 2: Participants will be enrolled in a text messaging intervention and sent an HPV self-sampling test kit to return via mail. Participants in the intervention group will receive the full mHealth intervention while the control group will receive more generic text messages and reminders over the course of the study.

Interventions

OTHERMySHARE+ mHealth Education Intervention

Participants in the intervention group will receive detailed pre-tested educational theory-based SMS messaging and education over the course of four weeks.

OTHERHealthcare Provider Prompt

Providers of healthcare and/or social services to WLH will complete an online survey to identify barriers to implementing an healthcare provider prompt in a primary care setting and participate in semi-structured interviews to provide feedback on drafted prompts. Prompts will be piloted at one local clinic to improve patient-provider communication about cervical cancer screening, followed with semi-structured interviews with providers involved.

Sponsors

Daisy Le
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Aim 1 Provider Prompt: Healthcare and/or service provider to women living with HIV Aim 2 RCT Pilot Inclusion Criteria: * Have an HIV diagnosis * Are between 30 to 65 years old * Have not had a Pap smear within the last 12 months or more.

Exclusion criteria

* Have had a history of hysterectomy or invasive cervical cancer * Are currently pregnant or were pregnant in the past 3 months * Are currently participating or enrolled in similar studies within the past year.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of participants who received and used the mailed HPV self-sampling kit.1 month, 3 months, and 6 monthsFeasibility of the mailed HPV self-sampling program: number of participants who received and used the HPV self-sampling test over the number of enrolled participants.
Proportion of participants who reported the presence of technical issues with the MySHARE+ messages.1 month, 3 months, and 6 monthsFeasibility of the MySHARE+ text-messaging program: number of participants who reported technical issues over the number of enrolled participants.
Proportion of participants who received all text messages and engaged with the MySHARE+ educational program.6 monthsFeasibility of the MySHARE+ text-messaging program: number of participants who received and engaged with 100% of the MySHARE+ messages over the number of participants enrolled in the text-messaging program.
Proportion of participants who were satisfied with the HPV self-sampling test.1 month, 3 months, and 6 monthsAcceptability of the HPV self-sampling test: number of participants satisfied with the HPV self-sampling test (e.g., understanding of instructions, ease of use, degree of pain and bleeding associated with use, and willingness to use self-sample HPV testing regularly using a 5-point Likert scale) over the number of enrolled participants.
Proportion of participants who were satisfied with the MySHARE+ text-messaging program1 month, 3 months, and 6 monthsAcceptability of the MySHARE+ text messaging program: number of participants with rated satisfaction items as four or higher from a 5-point Likert scale over the number of enrolled participants.
Proportion of participants who unsubscribed from the MySHARE+ text-messaging program.1 month, 3 months, and 6 monthsAcceptability of the MySHARE+ text messaging program: number of participants who unsubscribed from the MySHARE+ text-messaging program over the number of enrolled participants. An unsubscription rate of 15% or less will be considered acceptable
Proportion of participants who returned the HPV self-sampling test within three months of enrollment.1 month, 3 monthsPreliminary efficacy of the HPV self-sampling and the MySHARE+ mHealth program: number of participants who returned the HPV self-sampling test within three months of enrollment over the number of enrolled participants.

Secondary

MeasureTime frameDescription
Proportion of participants who completed an in-clinic follow-up Pap test since baseline.1 month, 3 months, and 6 monthsPreliminary efficacy of the HPV self-sampling and the MySHARE+ mHealth program: number of participants who completed an in-clinic Pap test over the number of enrolled participants.
Proportion of participants with an HPV positive test who completed an in-clinic follow-up Pap test since baseline.1 month, 3 months, and 6 monthsPreliminary efficacy of the HPV self-sampling and the MySHARE+ mHealth program: number of participants with an HPV positive test who completed an in-clinic Pap test over the number of participants with an HPV+ test.

Contacts

CONTACTDaisy Le, PhD, MPH/MA
daisyle@gwu.edu202-994-2061

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026